market research report : anti diabetic pharmaceuticals market in india 2015 - sample
TRANSCRIPT
Insert Cover Image using Slide Master View
Do not distort
Anti-Diabetic Pharmaceuticals Market – India
July 2015
2 ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
Drivers: Increase in the number of diabetic
patients
Introduction of newer and better drugs
Increasing aging population
Comprehensive health insurances policies covering diabetes
Drug Regulation and
Patents
Anti-diabetic pharmaceuticals market in India is valued at INR x bn in 2014
Market is expected to grow at a CAGR of x% from 2013 to 2018
Anti-diabetes therapeutic segment is the second fastest growing segment, after oncology
Challenges: Price regulation in insulin market
Use of complementary and alternative medicines
Maintenance of healthy lifestyle to avoid diabetes
Phases of clinical trial
Approval and licensing of drugs
Patents
Drivers & Challenges
Market
Executive Summary
Competition
Major Players
Company A Company C Company E
Company B Company D Company F
3
•Macroeconomic Indicators
•Introduction
•Market Overview
•Drivers & Challenges
•Government Initiatives
•Market Value Chain
•Regulation and Patents
•Competitive Landscape
•Strategic Recommendation
•Appendix
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
4
SAMPLE Macroeconomic Indicators (x/x)
Lending Rate: Annual
k l j i h g f e a d c b %
Per Annum
y1 2011-12
x2
y2
2014-15 y4
x4
2013-14 y3
x3
2012-13
x1
Max Min
Trade Balance: Annual
Commercial Bank Rates: Key Lending Rates as Prescribed by RBI (All Commercial Banks including SBI) - Minimum Rate General
N.B.: 2012-13 encompasses figure for Apr – Nov 2012
FDI: Annual
d
d
b
a
INR
tn
x3
2011-12
x1
2010-11
x2
2013-14
x4
2012-13
a
b
c
d
2010-11
y3
2011-12
y2
2012-13 2009-10
INR bn
y1 y4
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
5
SAMPLE The total diabetes market can be broadly classified into two parts
Oral anti-diabetic drug segment presents a huge opportunity for market players
Y X
Diabetes Market
YY XX
• Anti-diabetic pharmaceuticals occupy around x-y% of the market share, with oral drugs constituting around a-
b% of the market share
• Pharmaceutical sector is expected to be the largest source of product revenue over the next ten years
• Medical devices segment is composed of instruments for diagnosis and monitoring of the disease, and a range
of devices for administering insulin
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
6
SAMPLE The anti-diabetes pharmaceuticals consists of mainly six classes of drugs
Generic name
a1
How they work Trade name
Anti-diabetic medications treat Diabetes Mellitus by lowering glucose levels in the blood
A a2 a3
B b1 b2 b3
C c1 c2
d1
c3
D d2 d3
E e3 e1 e2
F f3 f1 f2
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
7
SAMPLE Increasing prevalence of diabetes is ensuring rapid growth for the global diabetes market
• XX
• XX
• XX
• XX
Global Market – Overview Market Size and Growth
Market Segmentation
a
c
d
b
0
x5 A
x3
INR tn
2014
x2
2018e
x6
2017e 2016e
x4
2015e 2013
x1
x
y
x
y
x y 2013 2015e
0
C
A
B
AFR
x6 x7
mn
SACA NAC
x5 x4
MENA
x3
EUR SEA
x2
WP
x1
People Living With Diabetes (2013)
Note: AFR – Africa, SACA – South & Central America, MENA – Middle East & North Africa, NAC – North America & Caribbean, EUR – Europe, SEA – South East Asia, WP – Western Pacific
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
8
SAMPLE India’s diabetes market is poised to grow over the coming years
Indian Market – Overview Market Size and Growth
Market Segmentation
h g a c b f d e
x7
%
CNS x4 CVS x3
x1
gastro
diabetes
x5 respiratory pain x6
x8 anti-infectives
x2 oncology
Growth in therapeutic segments(2010)
A
B
0
x1
2018e
X
2017e
x6 x5
2016e
INR bn
2013
x4
2015e
x3
2014
x2
x
y
x y
x y 2010 2015e
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
• XX
• XX
XX
XX
XX
9
SAMPLE The incidence of diabetes is higher in developed countries because of unhealthy lifestyles
North America and Caribbean 2013: x mn 2035e: y mn
Europe 2013: x mn 2035e: y mn
Africa 2013: x mn 2035e: y mn
Western Pacific 2013: x mn 2035e: y mn
Middle East and North America 2013: x mn 2035e: y mn
In 2013, there were ~x mn diabetics in the world, which is expected to increase to ~y mn by 2035
SEA and the Western Pacific Region together account for over x% of all people with undiagnosed diabetes
South East Asia 2013: x mn 2035e: y mn
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
South and Central America 2013: x mn 2035e: y mn
10
SAMPLE Huge increase in the number of diabetic patients promotes growth of the anti-diabetics pharmaceutical industry
• XX
• XX
Xx
Xx
Xx
• XX
• XX
• XX
Increase in the number of diabetic patients Impact
k r p h d i a g c e q f b m n u o l s j t
a9 Japan Egypt
a10
mn
a6
a3
China
USA
Germany a7
a2
a8 Indonesia
a4
Mexico RF
a1
a5
India
Brazil
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
Top 10 countries for number of people with diabetes (20-79 years)
Note: RF refers to Russian Federation
It is expected to increase to ~x mn by 2035
11
SAMPLE Price regulation in the insulin market and competition from alternative diabetes treatment hinders growth
• XX
Xx
Xx
Xx
Xx
Xx
xx
Price regulation in insulin market Impact
Competition from complementary and alternative medicines
• XX
Xx
Xx
Xx
Xx
Xx
• XX
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
12
SAMPLE Various initiatives taken by the government is providing a boost to this market
• XX
• XX • Xx
• Xx
• Xx
• Xx
• Xx
• XX • Xx
• Xx
• Xx
• Xx
• XX
• XX
Indian Council for Diabetic Care
NPCDCS
NRHM
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
13
SAMPLE Pharmaceutical value chains involve the entire process from drug discovery to drug marketing
X X X X X
A pharmaceutical value chain is a chain of activities which are involved in producing drugs, starting with raw materials and ending with the delivered product
XX XX XX XX XX
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
14
SAMPLE CDSCO, under the Ministry Of Health and Family Welfare, controls the drug control administration
• XX
• XX
• XX
• XX
• XX
• XX
• XX
• XX
• XX
• XX
Functions undertaken by Central Government Functions undertaken by the State Governments
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
The licensing and registration of pharmaceuticals in India controlled in a regulated way helps in the proper marketing of the drug continued
15
SAMPLE A
• XX
B • XX
• XX
2014
C • XX
D • XX
2013
E • XX
F • XX
G • XX
H • XX
2012
Some of the drugs approved for marketing in India (x/x)
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
16
SAMPLE Porter’s Five Forces Analysis
Competitive Rivalry • X Bargaining Power of Suppliers
• X Bargaining Power of Buyers
• X
Threat of Substitutes • X
Threat of New Entrants • X
Impact X
Impact X
Impact X
Impact X
Impact X
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
Note: CRO refers to contract research organization
17
SAMPLE Public Trading Comparables (FY 20--) – Top 3 Companies
Company A Company B Company C
Market Capitalization (INR mn) X X X
Share Price (INR) X X X
EV/EBITDA (INR mn) X X X
EV/Revenue (INR mn) X X X
PE Ratio X X X
Note: Top 3 Public companies based on the Market Capitalization; Share Price and PE ratio is as of 10/02/2015
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
Competitive Benchmarking (x/x)
18
SAMPLE
-20
-10
0
10
20
%
Company C
z2
z1
Company B
y2 y1
Company A
x2 x1
Net Margin Operating Margin
Key Ratios of Top 3 Companies – Operational Basis (FY 20--) (x/x)
• XX
• XX
• XX
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
Competitive Benchmarking (x/x)
19
SAMPLE Public: Domestic Company – Company A (1/4)
Key People
Products and Services
Company Information Offices and Centers – India
Corporate Address XX
Tel No. XX
Fax No. XX
Website XX
Year of Incorporation XX
Ticker Symbol XX
Stock Exchange XX
Name Designation
XX XX
XX XX
XX XX
Mumbai
Head Office
Category Products/Services
Pharmaceutical Products
XX
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
20
SAMPLE Key Ratios
Financial Summary
• The company earned a net profit of INR 2.7 bn in FY 2013, as compared to net profit of INR 1.8 bn in FY 2012
• The company reported total Income of INR 17.7 bn in FY 2013, registering an increase of 7.05% over FY 2012
• The company earned an operating margin of 17.30% in FY 2013, an increase of 3.21 percentage points over FY 2012
• The company reported a current ratio of 2.18 in FY 2013, an increase of 1.66% over FY 2012
Key Financial Performance Indicators
Net Profit / Loss Total Income
3
2
1
0
20
15
10
5
0
INR bn INR bn
2013
2.7
17.7
2012
1.8
16.5
2011
1.9
14.2
2010
2.3
11.8
Indicators Value (02/10/2015)
Market Capitalization (INR mn) 78,450.5
Total Enterprise Value (INR mn) 75,574.5
EPS (INR) 103.44
PE Ratio (Absolute) 32.96
Particulars y-o-y change
(2013-12) 2013 2012 2011 2010
Profitability Ratios
Operating Margin 3.21 17.30% 14.09% 16.04% 17.00%
Net Margin 4.31 15.02% 10.71% 13.48% 19.51%
Profit Before Tax Margin 4.70 20.56% 15.86% 20.03% 19.78%
Return on Equity 5.02 19.69% 14.67% 17.12% 22.75%
Return on Capital Employed 3.01 21.68% 18.68% 19.86% 19.83%
Return on Working Capital 6.97 59.72% 52.75% 73.42% 24.53%
Return on Assets 2.32 16.57% 14.25% 15.14% 14.28%
Return on Fixed Assets -62.36 36.61% 98.97% 121.08% 114.11%
Cost Ratios
Operating costs (% of Sales) -3.13 82.09% 85.22% 82.52% 82.42%
Administration costs (% of Sales)
-1.53 0.00% 1.53% 1.78% 2.24%
Interest costs (% of Sales) -0.07 0.02% 0.09% 0.03% 0.25%
Liquidity Ratios
Current Ratio 1.66% 2.18 2.14 1.87 3.08
Cash Ratio -45.26% 0.61 1.11 0.66 1.66
Leverage Ratios
Debt to Equity Ratio N.A. N.A. N.A. N.A. N.A.
Debt to Capital Ratio N.A. N.A. N.A. N.A. N.A.
Interest Coverage Ratio 360.14% 764.00 166.04 541.62 69.58
Efficiency Ratios
Fixed Asset Turnover -69.48% 2.04 6.70 6.93 6.49
Asset Turnover -4.07% 0.93 0.96 0.87 0.81
Current Asset Turnover -5.24% 1.80 1.90 1.95 0.94
Working Capital Turnover -6.57% 3.33 3.57 4.20 1.40
Capital Employed Turnover -3.00% 1.27 1.31 1.17 1.13
Improved Decline
Financial Snapshot
Public: Domestic Company – Company A (2/4)
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
21
SAMPLE Key Business Segments Key Geographic Segments
Business Highlights
Description News
Overview • XX
Diabetes Management • XX
Key Initiatives • XX
25%
82% 83% 75%
17%18%
100%
80%
60%
40%
20%
0%
2013 2012 2011
Outside India India
Public: Domestic Company – Company A (3/4)
80%
100%
60%
40%
20%
0%
2013
100% Pharmaceuticals
XX
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
22
SAMPLE Public: Domestic Company – Company A – SWOT Analysis (4/4)
• XX • XX
• XX • XX
T O
W S
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
23
SAMPLE Strategic Recommendations
• XX
Drug Market
• XX
In a highly competitive pharmaceutical industry, effective strategic decisions will help the players to gain a competitive advantage over others
Insulin Market
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015
24
The Anti-Diabetic Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Industry Series. For more detailed information or customized research requirements please contact:
Thank you for the attention
About Netscribes, Inc.
Netscribes, Inc. is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes, Inc. is a one-stop shop designed to fulfil clients’ profitability and growth objectives.
Phone: +91 22 4098 7600
E-Mail: [email protected]
ANTI-DIABETIC PHARMACEUTICALS MARKET IN INDIA 2015